Skip to main content

Table 7 Comparison of clinical effectiveness between TNF-i with MTX (n = 40) and TNF-i without MTX (n = 9)

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables

TNF-i without MTX (n = 9)

TNF-i with MTX (n = 40)

*P value

Cure of ulceration, n (%)

4/9 (44.4%)

21/40 (52.5%)

0.7252

Improvement of ulceration, n (%)

4/9 (44.4%)

23/40 (57.5%)

0.7126

Exacerbation of ulceration, n (%)

2/9 (22.2%)

10/40 (25%)

1.0000

Retention rate of TNF-i, n (%)

7/9 (77.8%)

33/40 (82.5%)

0.6631

Changes of DAIBD (month 0–1 year)

39.4 ± 35.7

44.5 ± 37.8

0.8460

Reduction in concomitant CS dose (month 0–1 year)

1.67 ± 3.53

6.13 ± 17.4

0.9191

CS less than 7.5 mg at year 1, n (%)

9/9 (100%)

36/40 (90.0%)

1.0000

  1. Plus-minus values are means ± standard deviation. *P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease